Monitor for results of the next preclinical study measuring energy expenditure and metabolic parameters, and for any IND filing or clinical trial initiation for SKNY-1. The company's market cap of $22M suggests any positive development could have outsized impact, but the data are very early stage.
Price Chart
Executive Summary
MIRA Pharmaceuticals announced initial positive proof-of-concept results from a pilot study of its oral obesity drug candidate SKNY-1 in diet-induced obese mice. The study showed statistically significant weight and fat reduction versus vehicle controls, with favorable lean-mass preservation and limited weight regain after discontinuation compared to semaglutide. These are early preclinical data with no financial figures or guidance provided.
Key Facts
- SKNY-1 demonstrated statistically significant reductions in body weight and fat mass in a DIO mouse model versus vehicle controls.
- Weight reduction occurred without a statistically significant decrease in food consumption, suggesting a potential metabolic mechanism beyond appetite suppression.
- SKNY-1-treated mice showed no statistically significant lean-mass loss versus controls, while semaglutide-treated mice did.
- After treatment discontinuation, SKNY-1-treated mice showed slow and limited weight regain; semaglutide-treated mice showed rapid and substantial weight rebound.
- MIRA is advancing SKNY-1 through longer-term preclinical studies and IND-enabling activities.
- No financial data, revenue, earnings, or guidance were provided in this filing.
Financial Impact
No financial figures disclosed; preclinical data only.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- SKNY-1 is at an early exploratory stage with no regulatory approvals or clinical data.
- The company has a small market cap ($22M) and may face financing needs to advance development.
- document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-048978 |
| Exhibit: ex99-1.htm | 0001493152-26-048978 |
| Document: 0001493152-26-048978-index-headers.html | 0001493152-26-048978 |
| Document: 0001493152-26-048978-index.html | 0001493152-26-048978 |
| Document: 0001493152-26-048978.txt | 0001493152-26-048978 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 today | Press Release | $0.5900 | awaiting T+5 | awaiting T+5 | $0.5560 (−5.76%) |
Oct 28, 2026 1d ago | 8-K | $0.5561 | awaiting T+5 | awaiting T+5 | $0.5560 (−0.02%) |
Oct 22, 2026 7d ago | 8-K | $0.6290 $0.5654 | ▼ −10.11% | ▼ −10.82% | $0.5560 (−11.61%) |
Oct 22, 2026 7d ago | Press Release | $0.6289 $0.5716 | ▼ −9.11% | ▼ −9.82% | $0.5560 (−11.59%) |
Sep 17, 2026 6w ago | 8-K | $0.7593 $0.8395 | ▲ +10.56% | ▲ +9.96% | $0.5560 (−26.77%) |
Sep 17, 2026 6w ago | Press Release | $0.7593 $0.8395 | ▲ +10.56% | ▲ +9.96% | $0.5560 (−26.77%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.7805 | ▼ −9.24% | ▼ −9.33% | $0.5560 (−35.35%) |
Aug 6, 2026 12w ago | 8-K | $0.6782 $0.7501 | ▲ +10.60% | ▲ +9.39% | $0.5560 (−18.02%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9337 | ▲ +1.00% | ▲ +1.56% | $0.5560 (−39.86%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9245 | ▼ −3.18% | ▼ −3.67% | $0.5560 (−41.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers